GSK

Business Context and Reporting Period

This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 18, 2004. The report primarily details changes in directors' interests in the company's ordinary shares and American Depositary Shares (ADSs), as well as a share buyback transaction executed in accordance with shareholder authority granted at the May 19, 2003 Annual General Meeting.

Key Financial Metrics

The filing does not provide consolidated financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only specific financial data points disclosed relate to share transactions:

• Share Buyback Price: 1,091.3635 pence per share.
• Share Buyback Volume: 900,000 ordinary shares purchased for cancellation.
• ADR Transaction Price: $42.52 per share (US Retirement Savings Plan).
• Share Sale Price: £11.06 per share (SmithKline Beecham Mid-Term Incentive Plan).

Material Changes

The filing reports several material changes regarding equity ownership and capital structure:

• Share Repurchase: The company reduced its share count by purchasing 900,000 ordinary shares for cancellation on February 17, 2004.
• Employee Trust Transactions: The GSK Trust and GSK US Trust executed multiple transfers and conversions of shares and ADSs to participants in various employee incentive plans (including the SmithKline Beecham Employee Share Option Plan 1991, Mid-Term Incentive Plan, and GlaxoSmithKline Performance Share Plan).
• Retirement Plan Holdings: The GlaxoSmithKline US Retirement Savings Plan increased its holdings of Ordinary Share ADRs from 18,460,173 to 18,505,813.

Guidance, Outlook, and Risks

The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. The document is strictly a regulatory disclosure of director interests and specific share transactions.

Investor Verification Checklist

• Verify the total number of shares outstanding following the cancellation of 900,000 shares.
• Confirm the aggregate value of the share buyback based on the disclosed price of 1,091.3635p.
• Review the specific impact of the GSK Trust and GSK US Trust transactions on the dilution or concentration of shares held by directors Dr. J-P Garnier, Dr. T Yamada, and Mr. J D Coombe.
• Check subsequent filings for the impact of these transactions on the company's overall capital structure.